MET-233i vs petrelintide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin receptor · full Obesity pipeline

MET-233i

Developed by Pfizer and partners

Phase 1/2 in Obesitypeptide
Weak signal

NCT07022977 · Phase 1 · completed

A randomised, double-blind single- and multiple-ascending-dose Phase 1 study in 144 otherwise healthy adults with obesity or overweight. Its primary endpoint is the occurrence of treatment-emergent adverse events and weight change is only secondary, so it is not efficacy evidence; no results are posted.

Next expected readout: January 2027 · NCT07725809 (registry estimate)

No aligned efficacy figure on record for this race.

petrelintide

Developed by Zealand Pharma and partners

Phase 3 in Obesitypeptide
Partial signal

NCT06662539 · Phase 2 · completed

The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent change from baseline in body weight to Week 28 (From Baseline (Day 1) to Week 28): Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). (met)

Result source: NCT06662539

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMET-233ipetrelintide
Body weight, % change—Not reported—Trial running · NCT07843485
Weight loss of 5% or more—Not reported—Trial running · NCT07843485
Weight loss of 10% or more—Not reported—Trial running · NCT07843485
Waist circumference, change (cm)—Not reported—Trial running · NCT07843485

Body weight, % change

MET-233i
—Not reported
petrelintide
—Trial running · NCT07843485

Weight loss of 5% or more

MET-233i
—Not reported
petrelintide
—Trial running · NCT07843485

Weight loss of 10% or more

MET-233i
—Not reported
petrelintide
—Trial running · NCT07843485

Waist circumference, change (cm)

MET-233i
—Not reported
petrelintide
—Trial running · NCT07843485
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

MET-233i: no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

petrelintide
Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). NCT06662539 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MET-233i's landscape · petrelintide's landscape